➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Colorcon
Dow
McKesson
Johnson and Johnson

Last Updated: May 9, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SAPHRIS

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Saphris

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00281320 Study of Asenapine in Elderly Subjects With Psychosis (A7501021)(P05717) Completed Merck Sharp & Dohme Corp. Phase 3 2006-02-01 This study evaluates the safety and tolerability of Asenapine in elderly patients with psychosis.
NCT00833976 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia Completed GlaxoSmithKline Phase 4 2009-07-01 This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.
NCT00833976 Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia Completed Massachusetts General Hospital Phase 4 2009-07-01 This is an open-label pilot study of omega-3 fatty acids (Lovaza) for hypertriglyceridemia in subjects who have been on an atypical (second-generation) antipsychotic medication. The investigators hypotheses are that patients who receive Lovaza will experience a significant decrease in triglycerides from baseline. Secondary hypotheses include: Patients will experience a significant decrease in total cholesterol, and Lovaza will be well tolerated.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Saphris

Condition Name

Condition Name for Saphris
Intervention Trials
Schizophrenia 4
Bipolar Disorder 3
Psychosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Saphris
Intervention Trials
Bipolar Disorder 4
Schizophrenia 4
Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Saphris

Trials by Country

Trials by Country for Saphris
Location Trials
United States 14
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Saphris
Location Trials
North Carolina 3
California 2
Georgia 2
Ohio 2
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Saphris

Clinical Trial Phase

Clinical Trial Phase for Saphris
Clinical Trial Phase Trials
Phase 4 6
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Saphris
Clinical Trial Phase Trials
Completed 10
Recruiting 1
Suspended 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Saphris

Sponsor Name

Sponsor Name for Saphris
Sponsor Trials
Merck Sharp & Dohme Corp. 7
Duke University 2
St. Joseph Hospital Health Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Saphris
Sponsor Trials
Industry 14
Other 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Express Scripts
AstraZeneca
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.